Susan Harold, MD
Hematology & Oncology · Detroit, MINPI 1093780611
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $5,080 and has fallen 85.7% since, to $725 in 2025. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $55.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- GSK$2K
- Gilead$2K
- AstraZeneca$1K
- AbbVie$825
- Sanofi$739
- plus $6K from 29 others
What the payments were for
- Speaking & faculty fees$2001%
- Food & beverage$13,81496%
- Education$3913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 20 | $2,077 |
| GSK | 91 | $1,931 |
| Gilead | 35 | $1,598 |
| AstraZeneca(2 entities) | 12 | $1,367 |
| AbbVie(2 entities) | 8 | $825 |
| Sanofi | 7 | $739 |
| Regeneron Healthcare Solutions, Inc. | 5 | $585 |
| Astellas Pharma US Inc | 5 | $560 |
| Eisai Inc. | 10 | $511 |
| Johnson & Johnson(2 entities) | 5 | $501 |
| Genentech USA, Inc. | 5 | $491 |
| Pfizer | 12 | $342 |
| Sobi, Inc | 3 | $319 |
| Merck | 3 | $246 |
| Amgen | 3 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $226 |
| Dova Pharmaceuticals | 7 | $219 |
| Lilly USA, LLC | 5 | $153 |
| CTI Biopharma Corp. | 1 | $130 |
| Incyte Corporation | 1 | $125 |
| Intercept Pharmaceuticals, Inc. | 1 | $124 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Novo Nordisk | 2 | $123 |
| Verastem, Inc. | 1 | $121 |
| Bayer | 1 | $114 |
| Pharmacosmos Therapeutics Inc. | 1 | $109 |
| Vifor Pharma, Inc. | 1 | $90 |
| Beigene USA, Inc. | 1 | $89 |
| AVEO Pharmaceuticals, Inc. | 2 | $85 |
| Foundation Medicine, Inc. | 1 | $81 |
| Tesaro, Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $38 |
| Azurity Pharmaceuticals, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,405 in reported general payments places this provider in the 90th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ReblozylLuspatercept-Aamt | 32 | $223,426 |
| OpdivoNivolumab | 11 | $167,005 |
| TasignaNilotinib Hcl | 13 | $123,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $93,136 |
| OzempicSemaglutide | 50 | $64,424 |
| TrulicityDulaglutide | 35 | $57,184 |
| EliquisApixaban | 24 | $26,259 |
| XareltoRivaroxaban | 28 | $24,984 |
| JardianceEmpagliflozin | 18 | $18,976 |
| TrintellixVortioxetine Hydrobromide | 18 | $16,636 |
| LinzessLinaclotide | 25 | $13,159 |
| EntrestoSacubitril/Valsartan | 13 | $8,601 |
| Erlotinib Hcl | 14 | $8,201 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $5,822 |
| Atorvastatin Calcium | 413 | $3,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Reblozyl, Opdivo | $2,077 | $390,43143 claims |
| GSKTrelegy Ellipta | $1,931 | $93,136145 claims |
| Novo NordiskOzempic | $123 | $64,42450 claims |
| Lilly USA, LLCTrulicity | $153 | $57,18435 claims |
| PfizerEliquis | $342 | $26,25924 claims |
| Johnson & JohnsonXarelto | $501 | $24,98428 claims |
| Boehringer IngelheimJardiance | $21 | $18,97618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $226 | $16,63618 claims |
| AbbVieLinzess | $825 | $13,15925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Detroit
- Mohammed Al HallakDetroit$644K
- Jeffrey ZonderDetroit$88K
- Hadeel AssadDetroit$80K
- Wasif SaifDetroit$44K
- Harsh ShahDetroit$38K
- Hirva MamdaniDetroit$28K
- Abhinav DeolDetroit$18K
- Lawrence FlahertyDetroit$18K
- Anthony ShieldsDetroit$12K
- Indryas WoldieDetroit$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.